Routine genomic testing of tumor tissue has expanded the treatment options for ovarian cancer patients, with the discovery of biomarkers including, but not limited to, BRCA1/2, HER2, TROP2, and FOLR1, all providing successful second-line treatments for patients developing this aggressive form of gynecologic tumors. Here, TACSTD2 is linked to ovarian carcinoma.